| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 ICRF Papillomavirus Group, Department of Biology, University College London, London WC1E 6BT
2 ICRF Tumour Virus Group, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, U.K.
3 Papillomavirus Research Unit, Lions Human Immunology Laboratories, University of Queensland, Princess Alexandra Hospital, Woolloongabba 4102, Australia
4 Ludwig Institute for Cancer Research, St Mary's Hospital Medical School, Norfolk Place, London W2 1PG
and5 ICRF Human Tumour Immunology Group, Courtauld Institute of Biochemistry, 91 Riding House Street, London W1P 8PT, U.K.
Immunization of mice with a recombinant vaccinia virus expressing the human papillomavirus type 16 (HPV-16) E6 gene elicits specific antibody, proliferative and cytotoxic T lymphocyte responses. T and B cell epitopes were mapped by using synthetic peptides. This study provides the background to future investigation aimed at developing prophylactic and therapeutic vaccines against HPV-16 infection and cervical cancer.
Present address: Department of Immunology, Windeyer Building, Cleveland Street, London WC1 6DB, U.K.
Received 10 April 1993;
accepted 30 August 1993.
This article has been cited by other articles:
|
|
 |
|
  Z. Chen, M. Terai, L. Fu, R. Herrero, R. DeSalle, and R. D. Burk Diversifying Selection in Human Papillomavirus Type 16 Lineages Based on Complete Genome Analyses J. Virol., June 1, 2005; 79(11): 7014 - 7023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-F. Chen, C.-W. Lin, Y.-P. Tsao, and S.-L. Chen Cytotoxic-T-Lymphocyte Human Papillomavirus Type 16 E5 Peptide with CpG-Oligodeoxynucleotide Can Eliminate Tumor Growth in C57BL/6 Mice J. Virol., February 1, 2004; 78(3): 1333 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Devaraj, M. L. Gillison, and T.-C. Wu DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA Crit. Rev. Oral. Biol. Med., September 1, 2003; 14(5): 345 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Steller Cervical Cancer Vaccines: Progress and Prospects Reproductive Sciences, September 1, 2002; 9(5): 254 - 264. [Abstract] [PDF]
|
|
|
|
|
|
D.-W. Liu, Y.-P. Tsao, C.-H. Hsieh, J.-T. Hsieh, J. T. Kung, C.-L. Chiang, S.-J. Huang, and S.-L. Chen Induction of CD8 T Cells by Vaccination with Recombinant Adenovirus Expressing Human Papillomavirus Type 16 E5 Gene Reduces Tumor Growth J. Virol., October 1, 2000; 74(19): 9083 - 9089. [Abstract] [Full Text]
|
|
|
|
|
|
D.-W. Liu, Y.-P. Tsao, J. T. Kung, Y.-A. Ding, H.-K. Sytwu, X. Xiao, and S.-L. Chen Recombinant Adeno-Associated Virus Expressing Human Papillomavirus Type 16 E7 Peptide DNA Fused with Heat Shock Protein DNA as a Potential Vaccine for Cervical Cancer J. Virol., March 15, 2000; 74(6): 2888 - 2894. [Abstract] [Full Text]
|
|
|
|
|
|
W. Shi, P. Bu, J. Liu, A. Polack, S. Fisher, and L. Qiao Human Papillomavirus Type 16 E7 DNA Vaccine: Mutation in the Open Reading Frame of E7 Enhances Specific Cytotoxic T-Lymphocyte Induction and Antitumor Activity J. Virol., September 1, 1999; 73(9): 7877 - 7881. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
